Autophagy in skeletal muscle: Implications for Pompe disease

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue SUPPL. 1, 2009, Pages

  Shea, L ^a   Raben, N ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Autophagy; Enzyme replacement therapy; Glycogen; Pompe disease; Skeletal muscle

Indexed keywords

ALPHA GLUCOSIDASE;

ANIMAL; AUTOPHAGY; ENZYME REPLACEMENT; GENETICS; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; METHODOLOGY; MOUSE; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SKELETAL MUSCLE; ULTRASTRUCTURE;

ALPHA-GLUCOSIDASES; ANIMALS; AUTOPHAGY; ENZYME REPLACEMENT THERAPY; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; MICE; MICE, KNOCKOUT; MUSCLE, SKELETAL;

EID: 77649200841     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp47042     Document Type: Conference Paper

References (24)

1. Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE, Veerling DL et al. Recombinant human acid α- glucosidase enzyme therapy for infantile glycogen storage disease Type II: results of a Phase I/II clinical trial. Genet Med. 2001; 3: 132-138.
2. Berg TO, Fengsrud M, Stromhaug PE, Berg T, Seglen PO. Isolation and characterization of rat liver amphisomes. Evidence for fusion of autophagosomes with both early and late endosomes. J Biol Chem. 1998; 273: 21883-21892. (Pubitemid 28405366)
3. Fukuda T, Ahearn M, Roberts A, Mattaliano RJ, Zaal K, Ralston E et al. Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease. Mol Ther. 2006a; 14: 831-819.
4. Fukuda T, Ewan L, Bauer M, Mattaliano RJ, Zaal K, Ralston E et al. Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease. Ann Neurol. 2006b; 59: 700-708.
5. Fukuda T, Roberts A, Ahearn M, Zaal K, Ralston E, Plotz PH et al. Autophagy and lysosomes in Pompe disease. Autophagy. 2006c; 2: 318-320. (Pubitemid 44342381)
6. Ghosh P, Dahms NM, Kornfeld S. Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol. 2003; 4: 202-212. (Pubitemid 36288042)
7. Griffin JL. Infantile acid maltase deficiency. I. Muscle fiber destruction after lysosomal rupture. Virchows ArchBCell Pathol Incl Mol Pathol. 1984; 45: 23-36. (Pubitemid 14175482)
8. Hirschhorn R, Reuser A. Glycogen storage disease Type II: acid α-glucosidase (acid maltase) deficiency. In: Scriver C, Beaudet A, SlyW, Valle D (eds). The metabolic and molecular bases of inherited disease. New York, NY: McGraw-Hill; 2001. p. 3389-3420.
9. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T et al. LC3, a mammalianhomologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000; 19: 5720-5728.
10. Kishnani PS, Nicolino M, Voit T, Rogers RC, Tsai AC, Waterson J et al. Chinese hamster ovary cell-derived recombinant human acid α-glucosidase in infantile- onset Pompedisease. J Pediatr. 2006; 149: 89-97. (Pubitemid 44081924)
11. Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL et al. Recombinant human acid α-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2007; 68: 99-109. (Pubitemid 46071892)
12. Kornfeld S. Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. Annu Rev Biochem. 1992; 61: 307-330.
13. Liou W, Geuze HJ, Geelen MJ, Slot JW. The autophagic and endocytic pathways converge at the nascent autophagic vacuoles. J Cell Biol. 1997; 136: 61-70. (Pubitemid 27044804)
14. Mizushima N. The pleiotropic role of autophagy: from protein metabolism to bactericide. Cell Death Differ. 2005; 12 (Suppl 2): 1535-1541. (Pubitemid 41553990)
15. Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell. 2004; 15: 1101-1111. (Pubitemid 38316219)
16. Moreland RJ, Jin X, Zhang XK, Decker RW, Albee KL, Lee KL et al. Lysosomal acid α-glucosidase consists of four different peptides processed from a single chain precursor. J Biol Chem. 2005; 280: 6780-6791. (Pubitemid 40341233)
17. Raben N, Danon M, Gilbert AL, Dwivedi S, Collins B, Thurberg BL et al. Enzyme replacement therapy in the mouse model of Pompe disease. Mol Genet Metab. 2003; 80: 159-169. (Pubitemid 37272242)
18. Raben N, Fukuda T, Gilbert AL, de Jong D, Thurberg BL, Mattaliano RJ et al. Replacing acid α-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen fromType II muscle fibers. Mol Ther. 2005; 11: 48-56. (Pubitemid 40011998)
19. Raben N, Takikita S, Pittis MG, Bembi B, Marie SK, Roberts A et al. Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand. Autophagy. 2007; 3: 546-552. (Pubitemid 350060050)
20. Thurberg BL, Lynch Maloney C, Vaccaro C, Afonso K, Tsai AC, Bossen E et al. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest. 2006; 86: 1208-1220. (Pubitemid 44789911)
21. Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, van der Ploeg AT. Recombinant human α-glucosidase from rabbit milk in Pompe patients. Lancet. 2000; 356: 397-398. (Pubitemid 30487498)
22. Van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, De Klerk JB, Loonen MC et al. Long-term intravenous treatment of Pompe disease with recombinant human α-glucosidase from milk. Pediatrics. 2004; 113: e448-e457.
23. Winkel LP, Kamphoven JH, van den Hout HJ, Severijnen LA, van Doorn PA, Reuser AJ et al. Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy. Muscle Nerve. 2003; 27: 743-751. (Pubitemid 36667485)
24. Wisselaar HA, Kroos MA, Hermans MM,van Beeumen J, Reuser AJ. Structural and functional changes of lysosomal acid α-glucosidase during intracellular transport and maturation. J Biol Chem. 1993; 268: 2223-2231. (Pubitemid 23033637)